Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments
31 October 2018 - 7:30AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, will present third
quarter 2018 results and corporate developments in a conference
call on Oct. 31, 2018 at 8 a.m. ET.
The investor presentation may be downloaded starting at 8 a.m.
ET from the Events and Presentations page of the Investor Relations
section of Intellia’s website at intelliatx.com.
To join the call:
- U.S. callers should dial 866-548-4713 and use conference ID#
5893807, approximately five minutes before the call.
- International callers should click here to access dial-in
information and use conference ID# 5893807, approximately five
minutes before the call.
A replay of the call will be available on Intellia’s website,
beginning on Oct. 31, 2018 at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases, or can replace patients’ diseased
cells. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
Intellia Contacts:
Investor
Contact:
Lindsey Trickett Vice President, Investor Relations +1
857-285-6211lindsey.trickett@intelliatx.com
Media Contact:Jennifer Mound Smoter Senior Vice
President, External Affairs & Communications +1 857-706-1071
jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024